Grants

  1. EU Horizon2020 Marie Sklodowska Curie European Training Program: MiND (to investigate pathomechanism of ADHD and ASD, local PI Andreas Reif):  The pan-European training network MiND (mastering skills in the training Network for attention deficit hyperactivity and autism spectrum Disorders) aims to educate a new generation of researchers in the field of neurodevelopmental disorders, through innovation-oriented research combined with highly interdisciplinary and intersectoral international training. Understanding the molecular, cellular and developmental bases of ADHD and ASD remains extremely challenging due to the limited availability of suitable model systems. The work package within the framework of the MiND project we are participating in will explore novel models for ADHD and ASD to provide insights into their pathology and facilitate translation of data to the bedside. At the Frankfurt site, the PhD student (Viola Stella Palladino) will generate primary human cell culture models for ASD and ADHD. Induced pluripotent stem cells (iPSCs) and iPSCs derived neuronal cells allow the functional consequences of genetic manipulations to be uncovered in human-derived tissue at the cellular level.

  2. Comorbid Conditions of ADHD (CoCA) (EU funding)

  3. AGGRESSOTYPE: The European Union Framework 7 project Aggressotype aims at investigating the biological basis of both the reactive (emotional, impulsive) aggression and the proactive (instrumental, predator) presentations of aggression, by employing highly innovative approaches in humans and animal models. This involves different levels of scrutiny, including genetics, brain imaging, epigenetics, work on neuron cell lines derived from stem cells or cognitive and behavioural assessments. Importantly, the consortium is committed to translate the preclinical findings into predictive, preventive and eventually therapeutic strategies, e.g. by using animal (mice, zebrafish) and cellular models to identify novel leads for treatment. The work package which we take part in focuses on the examination of the neurobiological mechanisms of aggression as a result of genetic variation in known and novel candidate genes. While work packages within the consortium identify genes moderating risk towards aggressive behaviours, with emphasis on specific aggression subgroups, our objective is to scrutinize the neurobiological sequelae of such genetic variants.

  4. Region-specific control of neuronal nitric oxide synthase (NOS-I) PDZ-interaction: implications in animal models of schizophrenia. In this research proposal we aim to address the role of neuronal nitric oxide synthase (NOS-I) and its protein interactions in the pathophysiology of schizophrenia. NOS-I interacts with several proteins including PSD-95 and NOS1AP to form a complex with NMDA receptors. Disturbed integrity of this complex was suggested to be involved in the development of schizophrenia. The project proposed herein aims to test this hypothesis by targeted modulation of NOS-I <> PDZ-interaction through viral gene transfer and its consequences on behavioral alterations in animal models of schizophrenia and comorbid disorders. When completed, this study will not only provide a mechanistic explanation for NOS-I function in the pathophysiology of schizophrenia, but also might open up a path to novel and innovative therapies for the treatment of these disorders. (DFG - funded since 2014)

  5. Frankfurter Nachwuchswissenschaftlerförderung: “Generation of a neuronal cell model of bipolar disorder to functionally characterize a DGKH risk gene variant”(to Sarah Kittel-Schneider): To functionally characterize one of the best replicated risk gene variants of bipolar disorder, DGKH, primary cell lines from risk gene and non-risk gene variant carriers are generated from fibroblast and PMBCs, reprogrammed into induced pluripotent stem cells and differentiated into neuronal cells. The primary cells lines, iPS and neuronal cells are further investigated morphologically and with immunhistochemistry and gene expression studies (microarray, quantitative RT PCR) to gain more knowledge about how this risk gene variant is conveying the risk of bipolar disorder on molecular level.

  6. Lithium-Studie: Randomized, Placebo-controlled Multicenter Trial of Lithium Plus Treatment as Usual (TAU) for Acute Suicidal Ideation and Behavior in Patients With Suicidal Major Depressive Episode (BMBF)

  7. BipoLife (BMBF)

  8. SIMaMCI: Trial of Simvastatin in Amnestic Mild Cognitive Impairment (MCI) Patients (SIMaMCI) (BMBF - funded since 2008)

  9. PReDicT: Predicting Response to Depression Treatment: The primary objective of the PReDicT project is to investigate the effects of a novel medical device – the PReDicT Test – to guide the antidepressant treatment of patients with a depressive disorder. The PReDicT Test consists of a computer-based facial emotional processing task and a standard questionnaire. The test may be used to significantly reduce the time required to identify effective pharmacological treatments for depressed patients and therefore to increase the proportion of patients showing a clinical response. The PReDicT study is a randomized, two-arm, multi-centre, open label, clinical investigation that will be conducted in depressed patients in primary and secondary care settings in five European countries (UK, France, Spain, Germany, and the Netherlands). Frankfurt is a participating site under the umbrella of P1vital Limited (UK), funded by the Horizon 2020 SME Instrument project grant (no. 696802) since 2016.

  1. PRADA (Prevalence of adult attention-deficit/-hyperactivity disorder in accident victims): Recent research shows an increased mortality in ADHD patients which is mainly due to accidents. The PRADA study is a prospective study to investigate the prevalence of adult ADHD in accident victims of three trauma surgery units (University Hospital Frankfurt, Hospital Sachsenhausen, BG Unfallkliniken Frankfurt). This study is sponsored by Medice. 

  2. VIP-ADHS: A study to investigate EEG-vigilance markers as response markers of methylphenidate treatment in adult ADHD